Keros Therapeutics, Inc.

NASDAQ:KROS

Biotechnology

Healthcare
$12.00 +1.20%

+$0.13 today

Market cap
$235.49M
Beta
0.96
P/E (TTM)
-4.6
EPS (TTM)
-$2.29
52W Low $9.69High $22.55

Volume 0.55M

Average 0.36M

KROS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Keros Therapeutics, Inc.NASDAQ: KROS

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -$5.92M, compared with $160.61M a year earlier. Trailing-twelve-month net change in cash was -$439.04M.

Context

  • Net change in cash amounted to 111.7% of revenue in FY2025, down 6339.6 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$5.92M or moves back toward the trailing-twelve-month quarterly average of -$109.76M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.92M-98.5% QoQ
Last fiscal yearDec 2025
-$272.52M-219.0% YoY
LTMMar 2026
-$439.04M-257.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-103.7%——
1 year-219.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(272.52M) USD
Year-over-year change
-219.0%

Net Change in Cash vs competitors

How KROS compares with its peers on the latest reported figures

  • KROS's LTM Mar 2026 net change in cash of $439.04M is the largest of the 10 companies compared; the peer median is $1.91M.
  • Its year-over-year change of -257.7% is the 8th highest of 10, against a peer median of -61.0%.
  • Net change in cash amounts to 1323.1% of revenue for KROS, versus a peer median of 74.1%.
KROS Competitors Peer median
Net Change in Cash for KROS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KROSKeros Therapeutics, Inc.LTM Mar 2026$439.04M -257.7%—1323.1%
RGNXREGENXBIO Inc.LTM Mar 2026$114.88M -770.6%-54.7%130.8%
ABSIAbsci CorporationLTM Mar 2026$54.44M +346.3%-43.2%2964.9%
VSTMVerastem, Inc.LTM Mar 2026$47.98M +36.3%+28.9%96.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$35.1M +1528.7%-56.4%—
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$26.92M +114.4%+69.8%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$21.32M -205.5%—7.1%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$18.28M -258.5%+28.0%51.4%
NAGENiagen Bioscience IncLTM Mar 2026$10.93M -61.0%—8.4%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$1.91M -88.7%——
Peer median (excluding KROS) $1.91M-61.0%-7.6%74.1%

Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.74M)(104.68M)(152.99M)(187.35M)87.01M
Depreciation & Amortization378K674K815K1.23M1.51M
Deferred Income Tax46K0000
Stock-Based Compensation11.72M18.68M28.76M34.87M28.7M
Change in Working Capital(16.07M)14.31M(2.65M)(11.44M)(12.11M)
Accounts Receivables(18M)18M(143K)(2.6M)(825K)
Inventory1.04M0(4.51M)00
Accounts Payables1.49M(408K)1.61M(249K)(3M)
Other Working Capital(597K)(3.28M)384K(8.59M)(8.29M)
Other Non-Cash Items520K953K1.56M1.82M2.4M
Operating Cash Flow(62.15M)(70.06M)(124.51M)(160.87M)107.51M
Capital Expenditures(1.02M)(1.24M)(2.46M)(1.93M)(1.55M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.02M)(1.24M)(2.46M)(1.93M)(1.55M)
Debt Repayment00000
Common Stock Issued28.17M119.58M175.83M380.13M(3.47M)
Common Stock Repurchased0000(375M)
Dividends Paid00000
Other Financing Activities379K731K3.13M11.69M0
Financing Cash Flow28.55M120.31M178.96M391.82M(378.47M)
Effect of Forex Changes00000
Net Change in Cash(34.62M)49.01M51.98M229.02M(272.52M)
Free Cash Flow(63.17M)(71.3M)(126.97M)(162.8M)105.95M

Keros Therapeutics, Inc.

NASDAQ:KROS

Intrinsic Alpha fair value

Locked

Current Price

$12.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.